

# Tobias Nordström

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9534392/publications.pdf>

Version: 2024-02-01

69  
papers

2,918  
citations

331670

21  
h-index

189892

50  
g-index

73  
all docs

73  
docs citations

73  
times ranked

4841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
2	Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. <i>Lancet Oncology</i> , The, 2015, 16, 1667-1676.	10.7	308
3	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
4	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 908-920.	27.0	184
5	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , 2015, 68, 139-146.	1.9	156
6	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 57-63.	3.9	134
7	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. <i>Genome Medicine</i> , 2018, 10, 85.	8.2	94
8	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
9	Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003–2011. <i>European Urology</i> , 2013, 63, 419-425.	1.9	85
10	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 1240-1249.	10.7	83
11	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , 2018, 74, 722-728.	1.9	70
12	The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>European Urology</i> , 2018, 74, 204-210.	1.9	68
13	The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. <i>European Journal of Cancer</i> , 2015, 51, 725-733.	2.8	61
14	Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. <i>Nature Communications</i> , 2017, 8, 14248.	12.8	58
15	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). <i>European Urology Oncology</i> , 2021, 4, 971-979.	5.4	56
16	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , 2018, 4, 707-710.	3.1	42
17	Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy-A 10-year population-based cohort study. <i>Prostate</i> , 2015, 75, 947-956.	2.3	37
18	Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. <i>Scandinavian Journal of Urology</i> , 2020, 54, 115-121.	1.0	36

#	ARTICLE	IF	CITATIONS
19	A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of $\geq 3$ ng/ml. <i>European Urology</i> , 2014, 65, 1184-1190.	1.9	32
20	Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. <i>Prostate</i> , 2016, 76, 339-348.	2.3	32
21	Risk of Prostate Cancer in Men Treated With 5 $\alpha$ -Reductase Inhibitors—A Large Population-Based Prospective Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1216-1221.	6.3	27
22	The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 137-142.	3.9	20
23	Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system—the Stavanger experience. <i>Scandinavian Journal of Primary Health Care</i> , 2020, 38, 315-322.	1.5	19
24	The economic burden of prostate cancer—a Swedish prevalence-based register study. <i>BMC Health Services Research</i> , 2020, 20, 448.	2.2	19
25	Association of 5 $\alpha$ -Reductase Inhibitors With Prostate Cancer Mortality. <i>JAMA Oncology</i> , 2022, 8, 1019.	7.1	18
26	Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. <i>JAMA Network Open</i> , 2019, 2, e1914689.	5.9	16
27	Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. <i>European Urology Focus</i> , 2021, 7, 546-553.	3.1	16
28	A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. <i>Scandinavian Journal of Urology</i> , 2016, 50, 104-109.	1.0	15
29	The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. <i>BMJ Open</i> , 2019, 9, e027958.	1.9	15
30	Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 640-647.	5.4	15
31	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. <i>European Urology Focus</i> , 2017, 3, 526-528.	3.1	14
32	Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw165.	6.3	13
33	A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019, 2, 490-496.	5.4	13
34	Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. <i>BMJ Open</i> , 2019, 9, e027816.	1.9	11
35	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50–69 years with PSA $\leq 3$ ng/ml. <i>Scandinavian Journal of Urology</i> , 2020, 54, 1-6.	1.0	11
36	The cost-effectiveness of prostate cancer screening using the Stockholm3 test. <i>PLoS ONE</i> , 2021, 16, e0246674.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 1797-1804.	2.2	10
38	Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. <i>European Urology Focus</i> , 2018, 4, 385-387.	3.1	9
39	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. <i>Journal of Clinical Pathology</i> , 2020, 73, 630-635.	2.0	9
40	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). <i>Journal of the National Cancer Institute</i> , 2021, 113, 632-640.	6.3	9
41	Association between PSA density and prostate cancer in men without significant MRI lesions. <i>BJU International</i> , 2020, 125, 763-764.	2.5	8
42	The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 394-394.	27.6	7
43	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. <i>PLoS ONE</i> , 2019, 14, e0218280.	2.5	7
44	Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>Value in Health</i> , 2021, 24, 1763-1772.	0.3	7
45	Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. <i>European Urology Focus</i> , 2019, 5, 842-848.	3.1	4
46	Real world treatment utilization patterns in patients with castration-resistant prostate cancer. <i>Scandinavian Journal of Urology</i> , 2021, 55, 299-306.	1.0	4
47	Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>European Urology</i> , 2022, 82, 12-19.	1.9	4
48	The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. <i>European Urology Open Science</i> , 2022, 41, 45-54.	0.4	4
49	External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort. <i>European Urology Open Science</i> , 2022, 41, 1-7.	0.4	4
50	Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. <i>BMC Urology</i> , 2017, 17, 92.	1.4	3
51	Towards Next-generation Urine-based Prostate Cancer Risk Stratification. <i>European Urology</i> , 2018, 74, 739-740.	1.9	2
52	Re: Tobias NordstrÅm, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik GrÅnberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139-46. <i>European Urology</i> , 2018, 74, e35-e36.	1.9	2
53	Improving GIS-based models for bicycling speed estimations. <i>Transportation Research Procedia</i> , 2019, 42, 85-99.	1.5	2
54	Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies. <i>World Journal of Urology</i> , 2021, 39, 1153-1159.	2.2	2

#	ARTICLE	IF	CITATIONS
55	Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. <i>European Urology Open Science</i> , 2021, 24, 11-16.	0.4	2
56	A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. <i>European Urology Open Science</i> , 2022, 38, 32-39.	0.4	2
57	Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 457-464.	3.9	1
58	Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16555-e16555.	1.6	1
59	Reply from Authors re: Goutham Vemana, Gerald L. Andriole. Bad Habits May Be Hard to Break. <i>Eur Urol</i> 2013;63:426-427. <i>European Urology</i> , 2013, 63, 427.	1.9	0
60	Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study. GrÅnberg H et al. <i>Lancet Oncology</i> . 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. <i>World Journal of Urology</i> , 2017, 35, 895-896.	2.2	0
61	Reply to Ola Bratt and Anna Åfverholm's Letter to the Editor re: Peter StrÅm, Tobias NordstrÅm, Henrik GrÅnberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2017.12.028">https://doi.org/10.1016/j.eururo.2017.12.028</a> . <i>European Urology</i> , 2018, 74, e10-e11.	1.9	0
62	Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. <i>BMC Urology</i> , 2019, 19, 73.	1.4	0
63	Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008-2016. <i>Journal of Radiation Oncology</i> , 2019, 8, 225-231.	0.7	0
64	Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik GrÅnberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>Eur Urol</i> 2018;74:722-728. <i>European Urology</i> , 2019, 75, e104-e105.	1.9	0
65	Response to Walsh. <i>Journal of the National Cancer Institute</i> , 2019, 111, 748-748.	6.3	0
66	Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) $\geq$ 7 prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 284-284.	1.6	0
67	The predictive value of DRE in the modern era of prostate cancer diagnostics.. <i>Journal of Clinical Oncology</i> , 2019, 37, 48-48.	1.6	0
68	MRI-targeted biopsies in prostate cancer screening and the value of its combination with blood-based risk-prediction: The randomized, diagnostic study STHLM3MRI.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS378-TPS378.	1.6	0
69	Incorporating mpMRI and biomarkers in active surveillance protocols: The prospective Stockholm3 Active Surveillance trial (STHLM3AS).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS379-TPS379.	1.6	0